{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:29:34Z","timestamp":1790990974432,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bisphosphonate-related osteonecrosis of the jaw (BRONJ) has been associated with long-term oral or intravenous administration of nitrogen-containing bisphosphonates (BPs). However, the pathogenesis of BRONJ remains unknown, and definitively effective treatment has not yet been established. Bisphosphonate-related osteonecrosis (BRON) tends to occur in maxillofacial bones. Why this occurs is still unclear. Here we show that zoledronate (Zol) treatment suppresses alveolar bone remodeling after tooth typical clinical and radiographic hallmarks of the human BRONJ, whereas enhances peripheral bone quantity in bone remodeling following injury in the same individuals, shown as increased cortical bone thickness, increased trabecular bone formation and accelerated bone defect repair. We find that the RANKL\/OPG ratio and Wnt-3a expression are suppressed at the extracted alveolar sites in Zol-treated rats compared with those at the injured sites of peripheral bones. We also show that Zol-treated bone marrow stromal cell (BMSCs) derived from jaw and peripheral bones exhibit differences in cell proliferation, alkaline phosphatase (ALP) activity, expression of osteogenic and chondrogenic related marker genes, and\n                    <jats:italic>in vivo<\/jats:italic>\n                    bone formation capacity. Hopefully, this study will help us better understand the pathogenesis of BRONJ, and deepen the theoretical research.\n                  <\/jats:p>","DOI":"10.1038\/srep36129","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T05:55:53Z","timestamp":1485842153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Skeletal Site-specific Effects of Zoledronate on in vivo Bone Remodeling and in vitro BMSCs Osteogenic Activity"],"prefix":"10.1038","volume":"7","author":[{"given":"Xue","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"key":"BFsrep36129_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bone.2011.02.011","volume":"49","author":"R Eastell","year":"2011","unstructured":"Eastell, R., Walsh, J. S., Watts, N. B. & Siris, E. Bisphosphonates for postmenopausal osteoporosis. Bone. 49, 82\u201388 (2011).","journal-title":"Bone"},{"key":"BFsrep36129_CR2","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/jbmr.438","volume":"26","author":"IR Reid","year":"2011","unstructured":"Reid, I. R. et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res. 26, 2261\u20132270 (2011).","journal-title":"J Bone Miner Res"},{"key":"BFsrep36129_CR3","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"89","author":"MT Drake","year":"2008","unstructured":"Drake, M. T., Clarke, B. L. & Khosla, S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 89, 1032\u20131045 (2008).","journal-title":"Mayo Clin Proc"},{"key":"BFsrep36129_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx, R. E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 61, 1115\u20131117 (2003).","journal-title":"J Oral Maxillofac Surg"},{"key":"BFsrep36129_CR5","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.amjmed.2008.12.005","volume":"122","author":"SL Silverman","year":"2009","unstructured":"Silverman, S. L. & Landesberg, R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 122, S33\u2013S45 (2009).","journal-title":"Am J Med"},{"key":"BFsrep36129_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0278-2391(09)00013-5","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update. J Oral Maxillofac Surg. 67, 2\u201312 (2009).","journal-title":"J Oral Maxillofac Surg"},{"key":"BFsrep36129_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1590\/1678-775720140506","volume":"23","author":"A Tardast","year":"2015","unstructured":"Tardast, A., Sj\u00f6man, R., L\u00f8es. S. & Abtahi, J. Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking. J Appl Oral Sci. 23, 310\u2013314 (2015).","journal-title":"J Appl Oral Sci."},{"key":"BFsrep36129_CR8","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/annonc\/mdl294","volume":"17","author":"T Van den Wyngaert","year":"2006","unstructured":"Van den Wyngaert, T., Huizing, M. T. & Vermorken, J. B. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol. 17, 1197\u20131204 (2006).","journal-title":"Ann Oncol"},{"key":"BFsrep36129_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.oooo.2015.10.033","volume":"121","author":"JP Bodem","year":"2016","unstructured":"Bodem, J. P. et al. Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III. Oral Surg Oral Med Oral Pathol Oral Radiol. 121, 367\u2013372 (2016).","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"BFsrep36129_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/annonc\/mdn630","volume":"20","author":"T Van den Wyngaert","year":"2009","unstructured":"Van den Wyngaert, T., Claeys, T., Huizing, M. T., Vermorken, J. B. & Fossion, E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 20, 331\u2013336 (2009).","journal-title":"Ann Oncol"},{"key":"BFsrep36129_CR11","doi-asserted-by":"crossref","unstructured":"Silva, M. L. et al. Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis. Clin Oral Investig. (2016).","DOI":"10.1007\/s00784-016-1778-3"},{"key":"BFsrep36129_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.actbio.2015.12.009","volume":"31","author":"H Yuan","year":"2016","unstructured":"Yuan, H. et al. Revival of nitrogen-containing bisphosphonate-induced inhibition of osteoclastogenesis and osteoclast function by water-soluble microfibrous borate glass. Acta Biomater. 31, 312\u2013325 (2016).","journal-title":"Acta Biomater."},{"key":"BFsrep36129_CR13","doi-asserted-by":"publisher","first-page":"e0144355","DOI":"10.1371\/journal.pone.0144355","volume":"10","author":"K Takaoka","year":"2015","unstructured":"Takaoka, K. et al. Establishment of an Animal Model of Bisphosphonate-Related Osteonecrosis of the Jaws in Spontaneously Diabetic Torii Rats. PLoS One 10, e0144355 (2015).","journal-title":"PLoS One"},{"key":"BFsrep36129_CR14","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina, C. V. et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 90, 1294\u20131301 (2005).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep36129_CR15","doi-asserted-by":"publisher","first-page":"20580","DOI":"10.1038\/srep20580","volume":"6","author":"D Sharma","year":"2016","unstructured":"Sharma, D., Hamlet, S. M., Petcu, E. B. & Ivanovski, S. The effect of bisphosphonates on the endothelial differentiation of mesenchymal stem cells. Sci Rep. 6, 20580 (2016).","journal-title":"Sci Rep"},{"key":"BFsrep36129_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000087286","volume":"69","author":"G Ferretti","year":"2005","unstructured":"Ferretti, G. et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology. 69, 35\u201343 (2005).","journal-title":"Oncology"},{"key":"BFsrep36129_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1177\/0960327115569808","volume":"34","author":"SS Soydan","year":"2015","unstructured":"Soydan, S. S. et al. Effects of alendronate and pamidronate on apoptosis and cell proliferation in cultured primary human gingival fibroblasts. Hum Exp Toxicol. 34, 1073\u20131082 (2015).","journal-title":"Hum Exp Toxicol"},{"key":"BFsrep36129_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1365-2141.2008.07504.x","volume":"144","author":"MA Scheper","year":"2009","unstructured":"Scheper, M. A., Badros, A., Chaisuparat, R., Cullen, K. J. & Meiller, T. F. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 144, 667\u2013676 (2009).","journal-title":"Br J Haematol"},{"key":"BFsrep36129_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.joms.2008.01.026","volume":"66","author":"R Landesberg","year":"2008","unstructured":"Landesberg, R. et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 66, 839\u2013847 (2008).","journal-title":"J Oral Maxillofac Surg"},{"key":"BFsrep36129_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","volume":"41","author":"IR Reid","year":"2007","unstructured":"Reid, I. R., Bolland, M. J. & Grey, A. B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 41, 318\u2013320 (2007).","journal-title":"Bone"},{"key":"BFsrep36129_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1177\/0022034515572021","volume":"94","author":"H Katsarelis","year":"2015","unstructured":"Katsarelis, H., Shah, N. P., Dhariwal, D. K. & Pazianas, M. Infection and medication-related osteonecrosis of the jaw. J Dent Res. 94, 534\u2013539 (2015).","journal-title":"J Dent Res"},{"key":"BFsrep36129_CR22","first-page":"977","volume":"29","author":"V Crincoli","year":"2015","unstructured":"Crincoli, V. et al. Microbiological investigation of medication-related osteonecrosis of the jaw: preliminary results. J Biol Regul Homeost Agents. 29, 977\u2013983 (2015).","journal-title":"J Biol Regul Homeost Agents"},{"key":"BFsrep36129_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","volume":"45","author":"P Lesclous","year":"2009","unstructured":"Lesclous, P. et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone. 45, 843\u2013852 (2009).","journal-title":"Bone"},{"key":"BFsrep36129_CR24","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1242\/dev.127.8.1671","volume":"127","author":"Y Chai","year":"2000","unstructured":"Chai, Y. et al. Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. Development. 127, 1671\u20131679 (2000).","journal-title":"Development"},{"key":"BFsrep36129_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nature01656","volume":"423","author":"JA Helms","year":"2003","unstructured":"Helms, J. A. & Schneider, R. A. Cranial skeletal biology. Nature. 423, 326\u2013331 (2003).","journal-title":"Nature"},{"key":"BFsrep36129_CR26","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1182\/blood.V87.10.4109.bloodjournal87104109","volume":"87","author":"P Charbord","year":"1996","unstructured":"Charbord, P., Tavian, M., Humeau, L. & P\u00e9ault, B. Early ontogeny of the human marrow from long bones: an immunohistochemical study of hematopoiesis and its microenvironment. Blood 87, 4109\u20134119 (1996).","journal-title":"Blood"},{"key":"BFsrep36129_CR27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.bone.2005.10.027","volume":"38","author":"SO Akintoye","year":"2006","unstructured":"Akintoye, S. O. et al. Skeletal site-specific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone 38, 758\u2013768 (2006).","journal-title":"Bone"},{"key":"BFsrep36129_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5114\/aoms.2015.50964","volume":"11","author":"M Kos","year":"2015","unstructured":"Kos, M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci. 11, 319\u2013324 (2015).","journal-title":"Arch Med Sci"},{"key":"BFsrep36129_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","volume":"1","author":"M Nakamura","year":"2015","unstructured":"Nakamura, M. et al. Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. J Pharm Health Care Sci. 1, 34 (2015).","journal-title":"J Pharm Health Care Sci"},{"key":"BFsrep36129_CR30","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","volume":"134","author":"K Zervas","year":"2006","unstructured":"Zervas, K. et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 134, 620\u2013623 (2006).","journal-title":"Br J Haematol"},{"key":"BFsrep36129_CR31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","volume":"65","author":"T Mavrokokki","year":"2007","unstructured":"Mavrokokki, T., Cheng, A., Stein, B. & Goss, A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 65, 415\u2013423 (2007).","journal-title":"J Oral Maxillofac Surg"},{"key":"BFsrep36129_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5114\/aoms.2015.50964","volume":"11","author":"M Kos","year":"2015","unstructured":"Kos, M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci. 11, 319\u2013324 (2015).","journal-title":"Arch Med Sci"},{"key":"BFsrep36129_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/clr.12502","volume":"27","author":"CL Li","year":"2016","unstructured":"Li, C. L. et al. Role of periodontal disease in bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats. Clin Oral Implants Res. 27, 1\u20136 (2016).","journal-title":"Clin Oral Implants Res"},{"key":"BFsrep36129_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1902\/jop.2013.130017","volume":"85","author":"V Thumbigere-Math","year":"2014","unstructured":"Thumbigere-Math, V. et al. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. J Periodontol. 85, 226\u2013233 (2014).","journal-title":"J Periodontol"},{"key":"BFsrep36129_CR35","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","volume":"142","author":"S Khosla","year":"2001","unstructured":"Khosla, S. Minireview: the OPG\/RANKL\/RANK system. Endocrinology 142, 5050\u20135055 (2001).","journal-title":"Endocrinology"},{"key":"BFsrep36129_CR36","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2165","volume":"9","author":"BF Boyce","year":"2007","unstructured":"Boyce, B. F. & Xing, L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 9, S1 (2007).","journal-title":"Arthritis Res Ther"},{"key":"BFsrep36129_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11420-007-9072-1","volume":"4","author":"PS Issack","year":"2008","unstructured":"Issack, P. S., Helfet, D. L. & Lane, J. M. Role of Wnt signaling in bone remodeling and repair. HSS J. 4, 66\u201370 (2008).","journal-title":"HSS J"},{"key":"BFsrep36129_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0070-2153(05)73002-7","volume":"73","author":"DA Glass","year":"2006","unstructured":"Glass, D. A. & Karsenty, G. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr Top Dev Biol. 73, 43\u201384 (2006).","journal-title":"Curr Top Dev Biol"},{"key":"BFsrep36129_CR39","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/jcb.21651","volume":"104","author":"M Eijken","year":"2008","unstructured":"Eijken, M. et al. Wnt signaling acts and is regulated in a human osteoblast differentiation dependent manner. J Cell Biochem. 104, 568\u2013579 (2008).","journal-title":"J Cell Biochem"},{"key":"BFsrep36129_CR40","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1359\/jbmr.060316","volume":"21","author":"NH Kulkarni","year":"2006","unstructured":"Kulkarni, N. H. et al. Orally bioavailable GSK-3alpha\/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo . J Bone Miner Res. 21, 910\u2013920 (2006).","journal-title":"J Bone Miner Res"},{"key":"BFsrep36129_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1196\/annals.1334.010","volume":"1049","author":"CA Gregory","year":"2005","unstructured":"Gregory, C. A. et al. How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Ann N Y Acad Sci. 1049, 97\u2013106 (2005).","journal-title":"Ann N Y Acad Sci"},{"key":"BFsrep36129_CR42","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2353\/ajpath.2010.090592","volume":"177","author":"Y Bi","year":"2010","unstructured":"Bi, Y. et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol. 177, 280\u2013290 (2010).","journal-title":"Am J Pathol"},{"key":"BFsrep36129_CR43","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1177\/0022034510378427","volume":"89","author":"TL Aghaloo","year":"2010","unstructured":"Aghaloo, T. L. et al. Osteogenic potential of mandibular vs. long-bone marrow stromal cells. J Dent Res. 89, 1293\u20131298 (2010).","journal-title":"J Dent Res"},{"key":"BFsrep36129_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1634\/stemcells.19-3-219","volume":"19","author":"EH Javazon","year":"2001","unstructured":"Javazon, E. H., Colter, D. C., Schwarz, E. J. & Prockop, D. J. Rat marrow stromal cells are more sensitive to plating density and expand more rapidly from single-cell-derived colonies than human marrow stromal cells. Stem Cells 19, 219\u2013225 (2001).","journal-title":"Stem Cells"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep36129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36129","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T20:12:56Z","timestamp":1671826376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep36129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,31]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,4,6]]}},"alternative-id":["BFsrep36129"],"URL":"https:\/\/doi.org\/10.1038\/srep36129","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,31]]},"assertion":[{"value":"25 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36129"}}